论文部分内容阅读
目的通过回顾性分析ABO、RhD配合型输血与同型输血(下简称“配合型输血或同型输血”)病例资料,以探讨配合型输血的安全性和有效性。方法对南昌地区2014年1月-2015年12月疾病治疗因素和特殊情况配合型输血的患者基本资料、红细胞计数(RBC)、血红蛋白浓度(Hb)、红细胞比容(Hct)和血小板计数(Plt)等有效性指标和输血前后Hb、间接胆红素(IBi L)、不规则抗体筛查、直接抗球蛋白试验(DAT)和输血不良反应等安全性指标与配比同型输血组进行病例对照分析,以探讨其安全性与有效性。结果 1)配合型输血与同型输血间输血前Hb、患者输血量、平均住院时间差异均不具统计学意义(P>0.05);2组输血患者均未发生输血不良反应;2)配合型输血组与同型输血组红细胞输注24 h后患者RBC、Hb、Hct值均明显升高,差异均具统计学意义(P<0.05),血小板输注24 h后患者Plt亦明显升高,差异具统计学意义(P<0.05);2组间输血24 h后增加值差异均不具统计学意义(P>0.05);3)29例配合型输血患者中,输血24 h后IBi L较输血前差异不具统计学意义(P>0.05),新生儿溶血病患者未检出新的其它不规则抗体,其它配合型输血患者DAT和不规则抗体均呈阴性;4)12例配合型输血患者输血后24h、d3、d7的Hb、IBi L间差异均不具统计学意义(P>0.05),未检测出新的其它不规则抗体。结论配合型输血与同型输血具有同等的安全性和有效性,特殊情况紧急抢救采取配合型输血是一种安全有效的临床输血治疗途径。
Objective To investigate the safety and efficacy of combined blood transfusion by retrospectively analyzing case data of ABO, RhD combined transfusion and homologous transfusion (hereinafter referred to as “combined transfusion or homologous transfusion”). Methods From January 2014 to December 2015 in Nanchang, the basic data of patients with disease treatment and special cases of combined blood transfusion, red blood cell count (RBC), hemoglobin concentration (Hb), hematocrit (Hct) and platelet count (Plt ) And other safety indicators before and after transfusion Hb, indirect bilirubin (IBi L), irregular antibody screening, direct antiglobulin test (DAT) and adverse reactions such as transfusion and other safety indicators with the same type of transfusion group for case control Analysis to explore its safety and effectiveness. Results 1) There was no significant difference in transfusion volume and average length of hospital stay among patients with transfusion of blood transfusion and those of the same transfusion group (P> 0.05). No transfusion adverse reactions were found in 2 transfusion patients. 2) RBC, Hb and Hct values were significantly increased in RBC, Hb and Hb after transfusion for 24 h in the same type of blood transfusion group, with statistical significance (P <0.05). Plt also increased significantly after platelet transfusion for 24 h (P <0.05). There was no significant difference in added value between the two groups after 24 h of transfusion (P> 0.05). 3) Among the 29 combined transfused patients, there was no difference between the two groups before transfusion for 24 h (P> 0.05). No other new irregular antibodies were found in newborn hemolytic patients, but DAT and irregular antibodies were negative in other patients with mixed transfusion; 4) The difference between Hb and IBi L of d3 and d7 was not statistically significant (P> 0.05), and no new other irregular antibodies were detected. Conclusion Combined transfusions have the same safety and effectiveness as blood transfusions. In special cases, emergency transfusion is a safe and effective clinical transfusion therapy.